Magazine article Medical Economics

Memorial Sloan-Kettering Cancer Center

Magazine article Medical Economics

Memorial Sloan-Kettering Cancer Center

Article excerpt


Today we cannot cure a man with metastatic prostate cancer," says Peter T. Scardino, MD, FACS, chairman of the Department of Surgery at Memorial Sloan-Kettering Cancer Center. However, he believes that continued aggressive efforts aimed at prevention, detection, diagnosis, and treatment will change the course of the disease for many men within the next 10 years.

The Sidney Rimmel Center for Prostate and Urologie Cancers at MSKCC strives to lead that change, in part through studies that identify men at increased risk of developing prostate cancer who might benefit from chemoprevention and a new study indicating that a single prostate-specific antigen test taken before age 50 can be used to predict advanced prostate cancer in men up to 25 years before a diagnosis.

Depth is the biggest strength of the prostate cancer program, Scardino says. It allows patients to find comprehensive treatment regardless of the stage of their disease or the type of treatment needed.

Each surgeon at MSKCC specializes in only one type of surgical technique for the treatment of prostate cancer and performs that technique exclusively- open, robotic, or laparoscopic. "That is a big strength and unique feature of the program," Scardino points out.

Patient care is backed by cuttingedge research. MSKCC hosts the world's largest prostate cancer clinical trial consortium, where researchers are investigating new treatments for advanced disease.

Hans Lilja, MD, PhD, a clinical laboratory physician at MSKCC, holds patents for his development of free prostate-specific antigen assays. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.